(MTNB) Matinas BioPharma Holdings, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MTNB) Matinas BioPharma Holdings, Inc. Complete Analysis Pack
Matinas BioPharma’s Business Model Canvas, in One Clear View
Unlock the full Business Model Canvas for Matinas BioPharma Holdings, Inc. and see how its value proposition, partnerships, and revenue logic fit together. This concise, company-specific blueprint helps you understand the strategy behind the science and the market opportunity ahead. Ideal for investors, analysts, and strategists who want actionable insight fast.
Partnerships
NIAID antiviral research collaboration
Matinas BioPharma’s NIAID antiviral research collaboration links the Company with a U.S. institute that received about $6.7 billion in FY2025 funding, adding outside validation for its platform and lowering technical risk. It also opens access to infectious-disease expertise and translational resources that can speed preclinical work into tests with higher scientific credibility.
Genentech oral-formulation feasibility work
Genentech’s oral-formulation feasibility work lets Matinas BioPharma Holdings, Inc. test its delivery platform on new small molecules, not just one lead asset. That matters because Matinas reported only modest revenue and ongoing losses in recent filings, so platform validation can support future licensing or co-development talks.
Clinical research organizations and trial sites
Matinas BioPharma Holdings, Inc. depends on clinical research organizations and trial sites to run Phase I and Phase II studies for MAT2203 and MAT2501, covering patient recruitment, monitoring, data capture, and GCP compliance. As a clinical-stage company with no commercial revenue, every study partner shortens the path to human data and regulator-ready results.
Manufacturing and CMC suppliers
Matinas BioPharma Holdings, Inc. depends on specialized CMC partners for drug substance, formulation, and analytical testing, which is central to its 2 lead oral anti-infective programs: oral amphotericin B and oral amikacin. Reliable manufacturing support also lowers scale-up risk for the LNC platform as the company moves from lab work to repeatable batch production.
- 2 lead programs depend on CMC partners
- Oral amphotericin B needs specialty formulation
- Oral amikacin needs testing and scale support
- LNC scale-up needs reliable manufacturing
Academic and translational collaborators
Academic and translational collaborators help Matinas BioPharma Holdings, Inc. test new indications and delivery formats for the LNC platform, using disease-model expertise to generate publication-quality data in 2 core areas: infectious and cardiometabolic disease.
- Validate LNC across new indications
- Support disease-model testing
- Produce publication-quality data
- Broaden platform credibility
Matinas Leans on Top Partners to De-Risk MAT2203 and MAT2501
Matinas BioPharma Holdings, Inc. relies on NIAID, Genentech, CROs, and CMC vendors to cut technical risk and move MAT2203 and MAT2501 toward human data. NIAID received about $6.7 billion in FY2025 funding, supporting deep infectious-disease expertise and translational access.
| Partner | Value |
|---|---|
| NIAID | FY2025 funding: $6.7B |
| Genentech | Oral-formulation feasibility |
| CROs/CMC | Phase I-II and scale-up support |
What is included in the product
Detailed Word Document
A concise, real-company Business Model Canvas mapping Matinas BioPharma’s strategy, value proposition, partners, channels, and revenue model.
Customizable Excel Spreadsheet
Quickly spot Matinas BioPharma’s key business model pain points and opportunities in one concise, editable snapshot.
Reference Sources
Provides a concise source trail for Matinas BioPharma Holdings, Inc., making key claims easier to verify and decisions easier to defend.
Activities
LNC platform development
Matinas BioPharma keeps improving its Lipid Nanocrystal (LNC) platform, which is built to deliver small molecules, nucleic acids, proteins, peptides, vaccines, and gene therapies. This is a core long-term bet: the company uses platform R&D to widen the addressable pipeline and support future partnering across multiple therapeutic classes.
Clinical development of MAT2203
MAT2203 is Matinas BioPharma Holdings, Inc.'s orally administered amphotericin B candidate and one of its most advanced assets. It is in Phase II for the prevention of invasive fungal infections in immunosuppressed patients, a high-risk group that includes transplant and oncology patients.
Clinical development of MAT2501
MAT2501, Matinas BioPharma Holdings, Inc.'s oral amikacin candidate, has completed Phase I testing and is being advanced for multidrug-resistant infections, including non-tuberculous mycobacteria and gram-negative pathogens. Next steps need clinical, CMC, and regulatory work, with development spending tied to trial design, manufacturing scale-up, and agency feedback.
Preclinical and formulation work for LYPDISO
Matinas BioPharma Holdings, Inc. is advancing LYPDISO, a proprietary prescription-grade omega-3 free fatty acid candidate, through preclinical and formulation work for cardiovascular and metabolic disorders. The activity centers on formulation, stability testing, and regulatory pathway planning to support the next development steps.
- Prescription-grade omega-3 candidate
- Targets cardio-metabolic disorders
- Focus on formulation and stability
- Builds regulatory path plans
Regulatory, IP, and partnership management
Matinas BioPharma Holdings, Inc. must keep patents, filings, and scientific disclosures aligned across its programs, while staying in sync with regulators and collaborators. This is central to moving assets forward and to monetizing the LNC platform, especially since the Company still has no approved products.
- Protect IP across all programs
- Manage regulatory filings and disclosure timing
- Coordinate with partners to advance and license the platform
Matinas BioPharma Advances LNC Platform and Pipeline
Matinas BioPharma Holdings, Inc. centers Key Activities on LNC platform R&D, clinical advancement of MAT2203 and MAT2501, and preclinical work on LYPDISO. It also runs CMC, regulatory, IP, and partner-facing work to move assets and support platform licensing.
| Activity | Current focus |
|---|---|
| LNC platform | Formulation and delivery R&D |
| MAT2203 | Phase II development |
| MAT2501 | Post-Phase I development |
| LYPDISO | Preclinical and formulation work |
Full Version Awaits
Business Model Canvas
This preview shows the actual Matinas BioPharma Holdings, Inc. Business Model Canvas you’ll receive after purchase. It is not a sample or mockup—what you see here is a direct view of the final document. Once you buy, you’ll get the same fully formatted file, complete and ready to use.
Resources
Lipid Nanocrystal platform IP
The Lipid Nanocrystal platform is Matinas BioPharma Holdings, Inc.'s core asset, and its patent estate is a key moat behind the oral and improved delivery of hard-to-formulate drugs. In 2025, the company still centered its strategy on this platform IP, since it can support higher-value drug programs without building a new delivery system from scratch.
MAT2203 development asset
MAT2203 is Matinas BioPharma Holdings, Inc.'s lead Phase II asset and the core of its infectious-disease pipeline. Its oral amphotericin B format targets the IV delivery problem that limits this antifungal, while also giving the program near-term clinical readouts and partnering appeal.
MAT2501 development asset
MAT2501 is Matinas BioPharma Holdings, Inc. oral amikacin asset for resistant bacterial infections, with Phase I complete and a clinical base for later studies. That de-risks the program and makes it a key resource for future anti-infective partnering as Matinas builds a pipeline beyond single-pathogen assets.
Scientific and management team
Matinas BioPharma Holdings, Inc. depends on a small scientific and management team to handle lipid-based formulation, clinical execution, and FDA-facing work across more than one program at a time. In FY2025, that human capital was the key asset for keeping development moving and for supporting partnering and financing talks.
- Formulation and regulatory know-how
- Runs multiple programs in parallel
- Supports partnering and fundraising
Bedminster, New Jersey headquarters
Matinas BioPharma Holdings, Inc.’s Bedminster, New Jersey headquarters is the company’s central hub for executive, admin, and development oversight, and it supports investor and partner communications. As a public biotech, this base anchors coordination around its 2025 SEC reporting and ongoing capital-markets work.
- Central operating location
- Exec and admin oversight
- Supports partner outreach
Matinas BioPharma’s Core Assets Power Its 2025 Growth Plan
Matinas BioPharma Holdings, Inc.’s key resources are its Lipid Nanocrystal platform, patent estate, and small team; these support MAT2203 and MAT2501 and the company’s 2025 regulatory and partnering work. The Bedminster, New Jersey base keeps clinical, admin, and investor functions in one place.
| Resource | Use |
|---|---|
| Lipid Nanocrystal platform | Oral delivery |
| Patent estate | IP moat |
| Small team | R&D and FDA work |
Value Propositions
Oral amphotericin B delivery
MAT2203 is built to turn amphotericin B, a hard-to-use antifungal, into an oral option, which could replace long IV infusions and improve convenience for patients. This matters in immunosuppressed groups, where invasive fungal infections can carry mortality above 40% and speed plus adherence are critical.
Oral amikacin for resistant infections
MAT2501 targets multidrug-resistant bacterial disease, and oral delivery could replace injectable aminoglycosides for patients who need longer or easier treatment. The value is strongest in hard-to-treat infections, where the CDC still estimates 2.8 million resistant infections and over 35,000 deaths a year in the US.
Broad LNC delivery versatility
Matinas BioPharma Holdings, Inc.’s LNC platform is built to carry multiple therapeutic modalities, so one delivery system can support both internal programs and outside partners across disease areas. With Matinas BioPharma Holdings, Inc. still pre-revenue in its latest reports, that versatility is the core value: it can help broaden pipeline shots on goal without building a new platform for each asset.
Prescription omega-3 cardiovascular candidate
LYPDISO is a prescription omega-3 candidate aimed at cardiometabolic disorders, using a proprietary free fatty acid profile to separate it from standard supplements. Prescription positioning can help Matinas BioPharma Holdings, Inc. stand out in a crowded omega-3 market by backing use with clinical evidence, dosing control, and physician oversight.
- Prescription use, not supplement style
- Targets cardiometabolic risk
- Proprietary omega-3 free fatty acid profile
- Built for clinical differentiation
Potential dosing, stability, and access benefits
Matinas BioPharma Holdings, Inc.’s oral delivery approach could cut treatment burden by replacing IV use and complex site-of-care logistics with simpler dosing. Better formulation can also help stability and handling, which matters in infectious-disease care where adherence and access can drive outcomes.
- Simpler oral dosing
- Less handling complexity
- Better storage stability
- Improved adherence potential
- Useful in infection care
Matinas Targets Hard-to-Treat Infections with Oral Drug Delivery
Matinas BioPharma Holdings, Inc. is positioned around oral delivery that can turn hard-to-use drugs like amphotericin B and aminoglycosides into easier, lower-burden options. Its value is strongest in severe infection care, where invasive fungal disease can have mortality above 40% and the CDC estimates 2.8 million resistant infections and 35,000 deaths a year in the US.
| Driver | Value |
|---|---|
| MAT2203 | Oral amphotericin B |
| MAT2501 | Oral MDR infection option |
| CDC US burden | 2.8M cases; 35,000 deaths |
Customer Relationships
Strategic B2B collaboration model
Matinas BioPharma Holdings, Inc. uses partner-led B2B relationships, not direct consumer sales, so customer ties are built around research, feasibility, and advancement milestones. As a clinical-stage biotech, it reported no product revenue in recent filings and relied on collaboration-driven development to move assets forward while preserving cash and limiting commercial risk.
Scientific collaboration support
Scientific collaboration support means Matinas BioPharma Holdings, Inc. must share data fast, align protocols, and review technical results with researchers and partners, often through repeated meetings as programs move through preclinical and clinical stages. This hands-on model builds platform credibility because partners judge the science by how well the team keeps studies aligned and decisions timely.
Clinical investigator engagement
Clinical investigator engagement is critical for Matinas BioPharma Holdings, Inc. because trial sites and investigators drive patient enrollment and data quality. The company must back them with study materials, training, and monitoring so sites can run smoothly and keep protocol deviations low; stronger investigator ties usually mean faster enrollment and cleaner trial execution.
Regulatory interaction model
Matinas BioPharma Holdings, Inc. keeps a long, compliance-heavy link with regulators: every study update, protocol change, and filing can trigger new questions and feedback, and biotech development often runs 10+ years before approval. That makes this relationship slow, formal, and central to keeping programs alive.
- Ongoing health-authority dialogue
- Answers to queries and submissions
- Protocol feedback and amendments
- Long-term compliance burden
Investor and public-market communication
Matinas BioPharma Holdings, Inc. uses investor and public-market communication to keep shareholders informed on clinical updates, financings, and strategic moves. As a small-cap biotech with a market cap below $100 million in recent public trading, steady disclosure matters because each update can move sentiment fast.
- Clinical data updates
- Financing and cash runway
- Strategic partnership news
- SEC filings and press releases
Matinas Builds Trust Through Data-Driven Biotech Partnerships
Matinas BioPharma Holdings, Inc. builds customer ties through collaboration, not sales, so relationships center on data sharing, protocol review, and milestone-based progress with research partners and trial sites. As a clinical-stage biotech with no product revenue in recent filings, it depends on long, compliance-heavy regulatory contact and clear investor updates to sustain funding and trust.
| Relationship | Focus |
|---|---|
| Partners | Data, milestones |
| Trial sites | Enrollment, quality |
| Regulators | Filings, compliance |
Channels
Direct business development outreach
Direct business development outreach lets Matinas BioPharma Holdings, Inc. approach pharma and biotech partners for licenses or collaborations, making partner talks the main route to monetize the platform. It is most useful for non-core assets and indications, where out-licensing can cut capital needs and speed value capture.
Clinical trial sites
Clinical trial sites, mainly hospitals and specialist centers, are Matinas BioPharma Holdings, Inc.'s operating channel for study execution; they link its assets to eligible patients and generate the clinical evidence needed for regulatory decisions. In 2025, patient screening and enrollment at each site remained the key bottleneck, so site quality and activation speed directly shaped trial timelines and data readouts.
Scientific conferences and publications
Scientific conferences and peer-reviewed publications help Matinas BioPharma Holdings, Inc. show data to researchers and potential partners, and they give the company a venue to validate its platform and programs in public. In infectious disease and drug delivery, published data carries real weight because it can move a candidate from early interest to credible scientific review.
Investor relations and SEC filings
Matinas BioPharma Holdings, Inc. uses SEC filings, earnings updates, and investor decks as a direct link to capital markets, where they shape valuation and financing access. These disclosures keep analysts focused on liquidity, dilution risk, and pipeline progress, which matters even more for a small-cap biotech with limited operating history.
- SEC filings drive market trust.
- Updates support financing talks.
- Presentations shape valuation views.
Partner and government networks
Existing collaborators can surface new programs fast, and government and research ties can also point Matinas BioPharma Holdings, Inc. to non-dilutive funding and translational routes. For a small biotech, this channel stays lean and practical when cash is tight and partner-led development is the main path forward.
- New opportunities can come from current partners.
- Research and government links can unlock funding.
- Low-cost channel for a small biotech.
Matinas’ Growth Hinges on Partners, Sites, and Investor Updates
Matinas BioPharma Holdings, Inc. relies on partner outreach, clinical sites, and public disclosure to move programs forward. In 2025, site activation and patient enrollment were the main trial bottlenecks, while SEC filings and investor decks stayed key for financing and valuation talks.
| Channel | Role |
|---|---|
| Partners | Licensing and collaboration deals |
| Trial sites | Patient enrollment and data generation |
| SEC and decks | Capital markets and investor access |
Customer Segments
Large pharmaceutical partners
Large pharmaceutical partners are Matinas BioPharma Holdings, Inc.’s main B2B customers because they can license the LNC platform or single programs, then bring late-stage development, approval work, and global sales. This matters in a market where the top 10 drugmakers each generate tens of billions of dollars in annual revenue, so one partner can fund scale fast.
Government and research institutions
Government and research institutions sponsor translational research when the science can speed public-health gains; NIAID, with a FY2025 budget request of about $6.6B, is a clear example. These buyers care most about scientific rigor, reproducibility, and evidence that a Matinas BioPharma Holdings, Inc. platform can support non-dilutive funding, collaborations, or contracts.
Biotech licensing and co-development partners
Biotech licensing and co-development partners are smaller biopharma companies that need better formulation or delivery tech, or want to pair on one therapeutic asset. This fits Matinas BioPharma Holdings, Inc.'s platform model, which is built to monetize its delivery IP through partnerships rather than only internal drug development.
Healthcare providers and specialty clinics
Healthcare providers and specialty clinics are the likely prescribers if MAT2203 or MAT2501 reach market, especially infectious-disease specialists and hospitals. They will weigh access, once-daily or easy dosing, and real-world effectiveness; for this segment, adoption depends on clinical data and payer coverage, not just the drug name.
- Key users: hospitals and ID specialists
- Decision drivers: access, dosing, efficacy
- Most relevant: MAT2203, MAT2501
Patients with high unmet need
Matinas BioPharma Holdings, Inc. targets patients with high unmet need: immunosuppressed people, fungal infection patients, and resistant-infection patients, where treatment failure is common and 1.27 million deaths were linked to antibiotic-resistant bacterial infections in 2019. Cardiometabolic patients also matter for LYPDISO, where need is a key part of the clinical case.
- High need, high failure risk
- Fungal and resistant infections
- Cardiometabolic use for LYPDISO
Matinas’ Growth Hinges on Pharma, Research, and Future Patients
Matinas BioPharma Holdings, Inc. sells mostly to pharma and biotech partners that can license its delivery tech, fund development, and push assets to market. It also serves government and research buyers for non-dilutive support, and future prescribers and patients if MAT2203, MAT2501, or LYPDISO reach approval.
| Segment | 2026/2025 cue |
|---|---|
| Pharma partners | Top 10 drugmakers exceed $20B sales each |
| Public research | NIAID FY2025 request: about $6.6B |
| Patients | 1.27M deaths from AMR in 2019 |
Cost Structure
Clinical trial expenses
Clinical trial expenses are usually Matinas BioPharma Holdings, Inc.’s biggest cost bucket, because Phase I and Phase II studies burn cash on sites, CROs, monitoring, data management, and patient support. In clinical-stage biotech, this spend can run into millions of dollars per program, and it often drives most of the R&D budget.
Research and formulation costs
Matinas BioPharma Holdings, Inc. channels research and formulation costs into platform science, drug delivery, and candidate optimization, including lab work, analytics, and preclinical studies. In biotech, these costs usually sit with the biggest cash burn; for Matinas, they also fund both internal assets and partner programs, so the spend drives value before any product revenue shows up.
Manufacturing and CMC costs
In fiscal 2025, Matinas BioPharma Holdings, Inc. remained a development-stage company, so manufacturing and CMC costs stayed a recurring R&D burden tied to outside vendors for drug substance production, formulation scale-up, and quality testing. This work is required to support clinical supply now and future commercialization later, and it applies across all programs.
General and administrative costs
Matinas BioPharma Holdings, Inc. general and administrative costs cover executive, finance, legal, SEC reporting, investor relations, and board work, and they stay material before any product sales. For a pre-commercial public Company, this overhead is a fixed cash drain that supports compliance and governance while clinical programs are still in flight.
- Exec, legal, and reporting overhead
- Investor relations and governance costs
- Hits cash burn before commercialization
IP, regulatory, and partnership costs
Patent prosecution, licensing work, and FDA/EMA filing prep are recurring cash costs for Matinas BioPharma Holdings, Inc. In a pre-revenue biotech, these IP and regulatory spend lines usually sit inside R&D and G&A, while partner deals add legal and business-development overhead.
- Protects platform rights
- Supports filings and reviews
- Enables partner monetization
Matinas FY2025: R&D Burn and Lean Overhead Drive Costs
In fiscal 2025, Matinas BioPharma Holdings, Inc. was still a pre-revenue biotech, so most costs sat in R&D: clinical trials, CMC work, lab science, and outside manufacturing. G&A stayed lean but fixed, covering SEC reporting, legal, finance, and governance.
| Cost area | FY2025 role |
|---|---|
| Clinical trials | Main cash burn |
| R&D and CMC | Platform and supply support |
| G&A | Public-company overhead |
| IP and regulatory | Protects and advances programs |
Revenue Streams
Collaboration and feasibility payments
Matinas BioPharma Holdings, Inc. can earn collaboration and feasibility payments from research partners that fund early testing and technical work; in biotech, these deals often add milestone cash before product sales start. Its Genentech and NIAID relationships fit this model, which is useful when internal revenue is still limited.
Government contract and grant funding
Government grants and contracts can fund specific research and translational work, so Matinas BioPharma Holdings, Inc. can advance programs with less internal cash burn. For example, NIH awards often support early-stage biotech work with non-dilutive capital, and that outside funding also signals that the science has medical relevance.
Upfront licensing fees
Upfront licensing fees are a likely cash source for Matinas BioPharma Holdings, Inc.'s LNC platform, since asset or platform deals can bring money in at signing. That cash can help fund development and trials before any product sales begin, which matters for a company still building its pipeline.
Milestone payments
Milestone payments let Matinas BioPharma Holdings, Inc. earn cash when partners hit development, regulatory, or launch goals, so revenue rises as programs move forward. This matters most for clinical-stage assets, where product sales can still be years away.
- Value tracks partner progress.
- Can include FDA or launch triggers.
- Best fit for clinical-stage programs.
Royalties and future product sales
Matinas BioPharma Holdings, Inc.’s royalty stream only starts if partnered programs reach market, so it is still future-based. Direct product sales also depend on FDA approval, launch, and scale-up, and the model remains pre-commercial with no recurring commercial revenue reported in its latest public filings.
- Royalties need partner success.
- Product sales need approval first.
- Current stream is still pre-commercial.
Matinas Still Relies on Partner Cash, Not Commercial Revenue
Matinas BioPharma Holdings, Inc. still relies on non-commercial revenue: collaboration fees, grants, upfront license payments, milestones, and future royalties or product sales. In its latest filings, recurring commercial revenue remains absent, so cash in 2025/2026 is still tied to partner progress and research funding.
| Revenue stream | Stage | Cash timing |
|---|---|---|
| Collaboration fees | Early R&D | Near-term |
| Grants | Non-dilutive | Project-based |
| Milestones/royalties | Partnered assets | Future |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.